4 completed, 3 recruiting, 3 unknown, 1 active not recruiting. 10 Phase 1, 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Recruiting 3, Completed 2, Unknown 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
Follow Celyad Oncology SA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer CYAD-101, FOLFOX, Pembrolizumab - Unresectable Metastatic Colorectal Cancer | Phase 1 | Recruiting | Celyad Oncology SA | 34 | 2021-11-22 | 2022-03-09 |
| Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma CYAD-211, Endoxan, Fludara - Relapse/Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Celyad Oncology SA | 18 | 2020-11-16 | 2023-08-31 |
| Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 CYAD-02, ENDOXAN, Fludara - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | Celyad Oncology SA | 27 | 2019-11-25 | 2020-06-09 |
| EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 NKR-2 CAR-T Cells - AML, Adult, Myelodysplastic Syndromes | Phase 1 | Withdrawn | Celyad Oncology SA | 2018-12-01 | 2019-10-29 | |
| alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells CYAD-101, FOLFOX, FOLFIRI - Unresectable Metastatic Colorectal Cancer | Phase 1 | Recruiting | Celyad Oncology SA | 49 | 2018-11-28 | 2020-11-20 |
| DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 NKR-2 - AML, MDS | Phase 1 / Phase 2 | Completed | Celyad Oncology SA | 21 | 2018-09-18 | 2021-05-04 |
| Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer NKR-2 cells - Colon Cancer Liver Metastasis | Phase 1 | Terminated | Celyad Oncology SA | 1 | 2017-10-11 | 2024-02-28 |
| Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases NKR-2 cells - Colon Cancer Liver Metastasis | Phase 1 | Unknown | Celyad Oncology SA | 36 | 2017-08-07 | 2020-06-16 |
| Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL Experimental, Sham comparator - Heart Failure | Phase 3 | Unknown | Celyad Oncology SA | 400 | 2017-06-01 | 2016-07-11 |
| A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications NKR-2 cells - Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM) | Phase 1 / Phase 2 | Unknown | Celyad Oncology SA | 146 | 2016-12-01 | 2019-09-19 |
| Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands CM-CS1 T-cell infusion - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Completed | Celyad Oncology SA | 12 | 2015-03-01 | 2018-06-01 |
| Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure. Injection of C3BS-CQR-1, Sham, no injection - Heart Failure | Phase 3 | Completed | Celyad Oncology SA | 315 | 2012-11-01 | 2018-06-01 |
| C-Cure Clinical Trial C-Cure - Heart Failure Class II or III | Phase 2 / Phase 3 | Completed | Celyad Oncology SA | 240 | 2008-12-01 | 2012-09-05 |
Heart Failure (3) · Leukemia, Myeloid, Acute (3) · Multiple Myeloma (3) · Myelodysplastic Syndromes (3) · GATA2 Deficiency (1) · Recurrence (1)
Cyclophosphamide (3) · fludarabine (3) · Folfox protocol (2) · fludarabine phosphate (2) · Azacitidine (1) · IFL protocol (1) · pembrolizumab (1) · salicylhydroxamic acid (1)
Belgium (10) · United States (7) · Serbia (2) · Bulgaria (1) · Hungary (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1) · Switzerland (1)
Frederic Lehmann, MD (2) · Jozef Bartunek, MD (1) · Jozef Bartunek, MD, PhD (1) · Sarah Nikiforow, MD; PhD (1)
PMID 23583246, PMID 26662998, PMID 29133316, PMID 30180944, PMID 35191428, PMID 36764323
R44HL099217 (1)